Research Use Only. IGF-1 LR3 is sold by Palmetto Peptides strictly for in vitro and preclinical laboratory research. It is not approved by the FDA for human or veterinary use. Nothing in this guide constitutes medical advice, dosage guidance, or encouragement to use this compound outside of an authorized research setting.

---

Palmetto Peptides Complete Guide to the Research Peptide IGF-1 LR3

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1 (IGF-1), engineered with two structural modifications — an arginine substitution at position 3 and a 13-amino acid N-terminal extension — that reduce its affinity for insulin-like growth factor binding proteins (IGFBPs) by approximately 1,000-fold and extend its biological half-life to roughly 20–30 hours. These properties make it one of the most widely used IGF-1 analogs in preclinical cell biology, tissue repair, and growth factor signaling research.

This guide covers everything a researcher needs to understand and work with IGF-1 LR3: what it is, how it works, how it differs from native IGF-1 and other analogs, how to handle and store it properly, what quality documentation to require, and what the published preclinical literature shows about its research applications.

---

Table of Contents

1. What Is IGF-1 LR3?
2. The Science Behind the Name: LR3 Structural Modifications
3. How IGF-1 LR3 Works: Receptor Binding and Downstream Signaling
4. IGF-1 LR3 vs. Native IGF-1: Key Research Differences
5. IGF-1 LR3 vs. IGF-1 DES: When Each Analog Fits
6. Half-Life and Stability: Why Duration Matters in Preclinical Research
7. Preclinical Research Applications
8. Lab Essentials: Reconstitution Protocol
9. Storage and Handling for Research Integrity
10. Purity Standards: What Receptor Grade Means
11. Sourcing IGF-1 LR3 for Research
12. Frequently Asked Questions
13. References

---

What Is IGF-1 LR3?

Insulin-like growth factor 1 (IGF-1) is a 70-amino acid peptide hormone produced primarily in the liver in response to growth hormone signaling. It plays a central role in regulating cell growth, survival, proliferation, and differentiation across virtually every tissue type in the body. Its receptor — IGF-1R, a transmembrane receptor tyrosine kinase — is expressed throughout the body, which is why IGF-1 signaling appears in research contexts ranging from muscle biology and bone formation to cancer cell biology and neuroscience.

IGF-1 LR3 (Long R3 IGF-1) is a recombinantly produced synthetic analog of this native peptide. The "LR3" designation encodes its two defining structural features:

• L (Long): A 13-amino acid synthetic leader sequence added to the N-terminus
• R3: Replacement of glutamic acid at position 3 with arginine

The result is an 83-amino acid peptide with a molecular weight of approximately 9.1 kDa — larger than native IGF-1 at 70 amino acids and ~7.6 kDa, but functionally distinguished by its dramatically reduced affinity for IGF binding proteins and its correspondingly extended biological half-life.

Why does that matter for research? In any biological system — cell culture with serum, or an in vivo model — the vast majority of native IGF-1 is immediately captured by IGFBPs (primarily IGFBP-3), which prevents it from reaching the IGF-1 receptor. In practice, this makes dosing unpredictable, half-life short, and dose-response data noisy. IGF-1 LR3 bypasses this problem, making it a cleaner, more reliable research tool in most experimental contexts.

Palmetto Peptides supplies IGF-1 LR3 research peptide with full lot-specific analytical documentation for authorized research programs.

---

The Science Behind the Name: LR3 Structural Modifications

Understanding what the two structural modifications of IGF-1 LR3 actually do — at the molecular level — helps researchers appreciate why the analog behaves differently from native IGF-1 in experimental systems.

The R3 Substitution: Disrupting IGFBP Recognition

Position 3 of the native IGF-1 sequence is occupied by glutamic acid (Glu, E) — a negatively charged residue located in the N-terminal loop of the peptide. This loop is a primary contact site for insulin-like growth factor binding proteins. The electrostatic properties of glutamic acid at position 3 contribute to the tight association between native IGF-1 and all six major IGFBPs.

In IGF-1 LR3, this residue is replaced with arginine (Arg, R) — a positively charged residue. The substitution disrupts the electrostatic fit required for IGFBP binding. It does not significantly affect the central beta-sheet core of the IGF-1 domain, which is where the IGF-1 receptor makes its primary contacts. The result: IGFBP affinity is reduced roughly 1,000-fold; IGF-1R binding is essentially preserved (Francis et al., 1992).

The N-Terminal Extension: Steric Interference

The 13-amino acid leader sequence (Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn-) added to the N-terminus of IGF-1 LR3 creates additional steric bulk at the N-terminus. IGFBPs have evolved to recognize the specific architecture of the native IGF-1 N-terminus — the extended leader sequence physically obstructs this recognition, compounding the disruption introduced by the R3 substitution.

Together, these two modifications work through different molecular mechanisms — electrostatic disruption plus steric interference — to achieve the observed ~1,000-fold IGFBP binding reduction while preserving receptor engagement.

For a full technical breakdown, see: Structural Modifications of IGF-1 LR3: Arginine Substitution and N-Terminal Extension Explained.

What Stays the Same

The three intramolecular disulfide bonds of native IGF-1 — which stabilize the three-dimensional fold of the peptide and are essential for IGF-1R binding — are preserved in IGF-1 LR3. The receptor-contact domain (central beta-sheet and C-domain) is unmodified. IGF-1 LR3 folds into the same overall architecture as native IGF-1 and engages the same receptor via the same primary contact surface.

---

How IGF-1 LR3 Works: Receptor Binding and Downstream Signaling

IGF-1 LR3 engages cells through the same receptor as native IGF-1: the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase embedded in the cell surface.

Receptor Activation

When IGF-1 LR3 binds to the extracellular alpha subunits of IGF-1R, the receptor undergoes a conformational change that triggers autophosphorylation of its intracellular beta subunits at multiple tyrosine residues. Think of this like pressing a start button — the phosphorylation event recruits adapter proteins and initiates a signaling cascade inside the cell (Adams et al., 2000).

The Two Primary Signaling Branches

From the activated IGF-1R, two major downstream pathways branch out — and both are critical to understanding what IGF-1 LR3 does in a research context:

PI3K/Akt Pathway (Cell Survival and Growth)

The PI3K/Akt pathway is the primary mediator of IGF-1R's cell survival effects. Activated IGF-1R phosphorylates IRS-1, which recruits PI3-kinase, which generates PIP3, which activates Akt (protein kinase B). Akt then promotes cell survival by suppressing pro-apoptotic proteins, drives protein synthesis through mTOR activation, and advances cell cycle progression.

In plain terms: this pathway keeps cells alive, makes them bigger, and helps them divide.

MAPK/ERK Pathway (Proliferation and Differentiation)

The MAPK/ERK cascade runs in parallel. Activated IGF-1R (via Shc and Grb2 adapter proteins) activates Ras, which activates Raf, which activates MEK, which activates ERK1/2. ERK then moves to the cell nucleus and activates transcription factors that drive gene expression changes associated with cell proliferation and differentiation — particularly in muscle, bone, and neural cell lineages (Coolican et al., 1997).

In plain terms: this pathway tells cells to multiply and specialize.

The Crosstalk Between Pathways

These two pathways are not independent — they interact. High Akt activity can partially suppress the MAPK/ERK output, creating a balance between proliferation-dominant and differentiation-dominant signaling states. Researchers designing mechanistic studies should account for this crosstalk when interpreting results from single-pathway inhibition experiments.

For a deeper mechanistic analysis with specific assay recommendations, see: IGF-1 LR3 Mechanism of Action in Cell Proliferation and Differentiation Research.

---

IGF-1 LR3 vs. Native IGF-1: Key Research Differences

The most important practical differences between IGF-1 LR3 and native IGF-1 for researchers are summarized here:

Property	Native IGF-1	IGF-1 LR3
Amino acids	70	83
Molecular weight	~7.6 kDa	~9.1 kDa
IGFBP affinity	High (binds all 6 IGFBPs)	~1,000x reduced
Free fraction in serum	~2%	Substantially higher
Biological half-life	~10–20 min (free form)	~20–30 hours
IGF-1R affinity	High	Slightly reduced, functionally comparable
Best use case	IGFBP biology studies; serum-free short-term assays	Sustained receptor activation; IGFBP-rich systems; multi-day protocols

The practical takeaway: in most preclinical research designs involving serum-containing media or in vivo models, IGF-1 LR3 delivers more predictable, consistent, and sustained IGF-1R activation than native IGF-1.

When might native IGF-1 be the better choice? When the research question involves IGFBP biology directly, when modeling native IGF-1 kinetics is the point of the study, or in short serum-free in vitro assays where IGFBP interference is not a meaningful variable.

For a complete comparison, see: IGF-1 LR3 vs Standard IGF-1: Structural Differences and Lab Research Implications.

---

IGF-1 LR3 vs. IGF-1 DES: When Each Analog Fits

Researchers comparing IGF-1 analogs will also encounter IGF-1 DES (DES(1-3) IGF-1) — a truncated variant that removes the first three N-terminal amino acids (Gly-Pro-Glu) of native IGF-1. Like IGF-1 LR3, DES reduces IGFBP binding and has been found naturally occurring in certain tissue environments. But the two analogs differ in important ways:

Property	IGF-1 LR3	IGF-1 DES
Structural change	13-aa extension + R3 substitution	3-aa N-terminal truncation
Length	83 amino acids	67 amino acids
IGFBP affinity reduction	~1,000x	Moderate (partial)
IGF-1R intrinsic affinity	Slightly reduced vs. native	2–10x higher than native
Estimated half-life	~20–30 hours	~20–30 minutes
Best fit	Multi-day protocols, IGFBP-rich systems, in vivo	Short-duration serum-free assays, CNS models, acute response studies

The key decision point: if you need sustained receptor activation over hours to days, IGF-1 LR3 is the more appropriate analog. If you need the highest possible intrinsic receptor affinity per unit dose in a serum-free system with a short time window, IGF-1 DES may perform better.

For a full comparative analysis, see: IGF-1 LR3 vs IGF-1 DES: Comparative Analysis for Preclinical Research Protocols.

---

Half-Life and Stability: Why Duration Matters in Preclinical Research

IGF-1 LR3's most practically significant property is its estimated biological half-life of 20–30 hours — versus roughly 10–20 minutes for free native IGF-1. That is approximately a 70–150x difference.

Why Such a Long Half-Life?

The native IGF-1 clearance mechanism relies primarily on IGFBP sequestration. The IGFBP-3/ALS ternary complex captures IGF-1 and ferries it into a biologically inactive reservoir. Because IGF-1 LR3 binds IGFBPs with 1,000-fold reduced affinity, this clearance mechanism is largely bypassed. The peptide persists in its free, receptor-active form far longer than native IGF-1 (Cascieri et al., 1988).

What This Means for Study Design

For multi-day cell culture protocols (muscle differentiation: 4–7 days; osteogenic differentiation: 14–21 days): a single daily addition of IGF-1 LR3 can maintain above-threshold receptor occupancy throughout the protocol, whereas native IGF-1 would require frequent replenishment.

For in vivo preclinical models: reduced administration frequency means less handling stress on animals and more stable steady-state receptor engagement between doses.

For dose-response experiments: longer persistence means less variability in effective concentration at different time points within an experiment.

One consideration worth noting: the extended half-life is an advantage in most designs but a factor to manage in washout experiments, where rapid signal termination is required. In those cases, native IGF-1 or IGF-1 DES may be more appropriate.

It is also important to distinguish biological half-life (how long IGF-1 LR3 remains receptor-active in a biological system) from chemical storage stability (how long the molecule remains structurally intact in solution or lyophilized form). The former is long; the latter still requires careful cold storage management.

For detailed analysis, see: IGF-1 LR3 Research Peptide Half-Life and Stability Advantages for Long-Term Lab Studies.

---

Preclinical Research Applications

IGF-1 LR3 has been applied across a wide range of preclinical tissue and cell biology research models. Its extended half-life and IGFBP-bypassing properties make it particularly well-suited for the long-duration, serum-containing culture conditions common in tissue repair and regeneration research.

Skeletal Muscle Research

IGF-1 signaling is a central regulator of the satellite cell activation and myoblast differentiation cycle. In C2C12 and L6 myoblast culture models, IGF-1 LR3 is commonly used to accelerate myogenic differentiation, increase myotube formation and hypertrophy, and enhance markers of protein synthesis including myosin heavy chain expression (Florini et al., 1996).

The IGFBP-bypassing property is especially relevant in myoblast cultures, which are known to secrete significant amounts of endogenous IGFBPs — making native IGF-1 dose-response data particularly unreliable compared to IGF-1 LR3.

Bone Biology Research

Osteoblast differentiation from mesenchymal precursors is driven in part by IGF-1R signaling, which promotes survival, matrix synthesis, and mineral deposition. In primary osteoblast and MC3T3-E1 cultures under osteogenic conditions, IGF-1 LR3 is used to study the IGF-1R contribution to alkaline phosphatase activity, osteocalcin expression, and calcium mineralization (Zhao et al., 2000). The 14–21 day timeline of osteogenic protocols makes IGF-1 LR3's long half-life particularly valuable.

Cartilage and Chondrocyte Research

In primary articular chondrocyte and MSC chondrogenesis models, IGF-1 LR3 promotes matrix synthesis — particularly aggrecan and type II collagen production — and supports chondrocyte survival in the serum-free or low-serum conditions that mimic cartilage's avascular environment (Loeser et al., 2014).

Wound Healing and Dermal Research

In dermal fibroblast scratch assays and proliferation studies, IGF-1 LR3 stimulates cell migration and collagen synthesis, supporting mechanistic work on the proliferative phase of wound repair.

Protein Production and Bioreactor Applications

IGF-1 LR3 is a well-established supplement in CHO cell bioreactor culture, where its extended half-life reduces the frequency of growth factor replenishment needed to maintain cell viability and productivity. This is one of the more commercially established applications of the analog.

For a detailed review of tissue-specific research models and study design considerations, see: Applications of IGF-1 LR3 Research Peptide in Preclinical Tissue Repair and Regeneration Studies.

---

Lab Essentials: Reconstitution Protocol

Proper reconstitution is one of the most consequential handling steps in IGF-1 LR3 research. The wrong solvent, aggressive mixing, or improper post-reconstitution handling can degrade the peptide before it ever reaches a cell.

Recommended Solvent

10 mM HCl (dilute hydrochloric acid in sterile water) is the standard reconstitution vehicle for IGF-1 LR3. Its mild acidity protonates surface residues and promotes full solubility. 1% acetic acid in sterile water is an acceptable alternative.

Avoid: neat DMSO (disrupts disulfide bonds), PBS alone (aggregation at neutral pH before dissolution), alkaline buffers (deamidation risk).

Working Concentration

Most cell culture protocols use IGF-1 LR3 at final concentrations of 10–100 ng/mL. A practical stock solution is 0.1–1 mg/mL, prepared in 10 mM HCl and diluted in stages to the working concentration.

Step-by-Step Protocol

1. Equilibrate the sealed lyophilized vial to room temperature (15–20 min) before opening
2. Centrifuge briefly (30 sec at 1,000–2,000 rpm) to consolidate powder
3. Add solvent gently against the side of the vial — not directly onto the powder
4. Roll the vial gently between your palms for 30–60 seconds; do not vortex
5. Allow to sit for 2–5 minutes, then inspect — solution should be clear and colorless
6. If using for cell culture, pass through a 0.22 µm low-protein-binding syringe filter
7. Aliquot immediately into single-use low-binding microcentrifuge tubes
8. Flash freeze aliquots in liquid nitrogen or dry ice/ethanol before moving to -80°C storage

For the complete protocol with troubleshooting guide, see: How to Reconstitute IGF-1 LR3 Research Peptide: Step-by-Step Lab Protocol.

---

Storage and Handling for Research Integrity

Lyophilized (Before Reconstitution)

Condition	Recommendation
Temperature	-20°C (routine) or -80°C (extended)
Light	Protect from light
Humidity	Low humidity; keep sealed until use
Shelf life	Up to 2 years at -20°C (sealed, properly stored)

Never store lyophilized peptides in a frost-free (auto-defrost) freezer. The temperature cycling that keeps the freezer ice-free introduces repeated mini freeze-thaw events that degrade the compound over time even without opening the vial.

Reconstituted (After Dissolution)

Form	Temperature	Stability
Aliquoted stock (10 mM HCl)	-80°C	3–6 months
Aliquoted stock (10 mM HCl)	-20°C	1–3 months
Working dilution in buffer	4°C	24–48 hours max

Key rules:

• Aliquot before freezing — eliminate unnecessary freeze-thaw cycles
• Flash freeze aliquots; thaw at 4°C (not room temperature)
• Discard after 2 freeze-thaw cycles
• Use low-protein-binding tubes to prevent peptide adsorption to tube walls
• Never store working dilutions in serum-containing media

For the complete storage guide including degradation pathway chemistry and container selection, see: Optimal Storage and Stability Guidelines for IGF-1 LR3 Lyophilized Research Peptide.

---

Purity Standards: What Receptor Grade Means

In the context of IGF-1 LR3 research peptides, "receptor grade" refers to a preparation that meets the following minimum standards:

• HPLC purity: ≥98% by peak area — the dominant species accounts for at least 98% of total detected material
• Mass spectrometry identity: observed MW ~9,111 Da — within 0.1% of the theoretical molecular weight, confirming correct molecular identity
• Endotoxin: <1 EU/mg — bacterial LPS contamination below the threshold that would activate innate immune pathways in standard cell culture

Why Each Standard Matters

HPLC purity matters because truncated sequences, oxidized variants, and related impurities can act as partial agonists or antagonists at IGF-1R, shifting dose-response curves and producing data that does not replicate.

Mass spectrometry confirmation matters because HPLC alone cannot distinguish the correct compound from a co-eluting impurity of similar hydrophobicity. MS confirms the dominant peak is actually IGF-1 LR3.

Endotoxin testing matters because even trace LPS contamination — at concentrations as low as 0.1 ng/mL — can activate NF-κB and other innate immune signaling pathways that intersect directly with the proliferation and survival biology IGF-1 LR3 research most commonly studies. An endotoxin-contaminated preparation can generate results that look biological but are artifacts of LPS signaling.

One additional consideration: disulfide isomers — non-native disulfide bond pairings resulting from incomplete refolding during manufacturing — can produce peptide that passes HPLC purity testing but binds IGF-1R poorly. Requesting mass spectrometry data under both reducing and non-reducing conditions, or asking for bioactivity verification data, provides additional confidence in these cases.

For the full purity analysis framework, see: Receptor Grade IGF-1 LR3 Research Peptide: Why Purity Standards Matter in Experiments and Quality Testing and Third-Party Verification for IGF-1 LR3 Research Peptides.

---

Sourcing IGF-1 LR3 for Research

The research peptide market varies widely in quality, documentation standards, and regulatory positioning. For researchers whose work depends on reproducible results, sourcing decisions are not a background consideration.

Non-Negotiable Criteria

Third-party analytical verification. A supplier testing their own products in-house is providing self-attestation, not independent verification. Third-party testing — HPLC, mass spectrometry, and LAL endotoxin assay performed by a named, independent laboratory — is the standard that counts. Ask for the testing laboratory name before ordering.

Lot-specific certificates of analysis. Generic or template-filled CoAs with round-number purity values and no chromatogram reference are a red flag. A genuine CoA has a unique lot number, actual measured purity values, and MS data.

Research-use-only compliance. Any supplier providing dosage guidance for human use, marketing to general consumers, or positioning IGF-1 LR3 as a wellness or performance product is operating outside appropriate regulatory boundaries. Do not purchase from such sources.

Cold-chain shipping. Lyophilized peptides are more stable than reconstituted solutions, but temperature-managed shipping (cold packs or dry ice) is still the appropriate standard for research-grade compounds.

Supplier Evaluation Checklist

• [ ] Third-party HPLC (≥98%) with named external laboratory
• [ ] Mass spectrometry identity confirmation (~9.1 kDa)
• [ ] Endotoxin result (numerical EU/mg, not just "pass")
• [ ] Lot-specific CoA with unique lot number
• [ ] Research-use-only language on all product pages
• [ ] No human dosage implications anywhere on the site
• [ ] Temperature-managed shipping available
• [ ] Responsive technical support

For a full sourcing framework, see: How to Choose a Trusted Supplier for IGF-1 LR3 Research Peptides in 2026 and Buying IGF-1 LR3 Online for Research: Key Factors Researchers Should Consider.

Palmetto Peptides provides IGF-1 LR3 research peptide with independent third-party analytical documentation per lot. We also supply related compounds including IGF-1 DES, standard IGF-1, and other IGF analog research peptides for comparative research protocols.

---

Supporting Research Articles

• IGF-1 LR3 Mechanism of Action
• IGF-1 LR3 vs Standard IGF-1
• IGF-1 LR3 Structural Modifications
• IGF-1 LR3 Half-Life and Stability
• IGF-1 LR3 Tissue Repair Research
• IGF-1 LR3 vs IGF-1 DES
• IGF-1 LR3 Reconstitution Guide
• IGF-1 LR3 Storage and Stability
• IGF-1 LR3 Quality Testing
• IGF-1 LR3 Purity Standards
• Sourcing High-Purity IGF-1 LR3
• Buying IGF-1 LR3 Online

Frequently Asked Questions

Q: What is IGF-1 LR3? A synthetic 83-amino acid analog of human IGF-1, engineered with reduced IGFBP binding (~1,000x lower than native) and an extended biological half-life of ~20–30 hours. Used exclusively for preclinical and in vitro research.

Q: How does it differ from standard IGF-1? Standard IGF-1 has high IGFBP affinity and a free-form half-life of ~10–20 minutes. IGF-1 LR3 bypasses IGFBP sequestration and persists for ~20–30 hours, making it more reliable for sustained receptor activation in serum-containing research systems.

Q: What signaling pathways does it activate? PI3K/Akt (cell survival, protein synthesis, proliferation) and MAPK/ERK (proliferation, differentiation) via IGF-1R.

Q: What is the half-life of IGF-1 LR3? ~20–30 hours in in vivo biological systems, approximately 70–150x longer than free native IGF-1.

Q: How do I reconstitute it? In 10 mM HCl using gentle rolling (not vortexing). Aliquot immediately; store at -80°C.

Q: What purity should it meet? ≥98% HPLC, MS identity ~9,111 Da, endotoxin <1 EU/mg, all from an independent third-party laboratory.

Q: What are its research applications? Skeletal muscle differentiation, bone biology, cartilage research, wound healing models, and bioreactor cell culture.

Q: Is it approved for human use? No. Research use only, not approved for human or veterinary applications.

Q: How does it differ from IGF-1 DES? IGF-1 LR3 is longer (83 aa), has superior IGFBP resistance, and a much longer half-life (~20–30 hours). IGF-1 DES is shorter (67 aa), has higher intrinsic IGF-1R affinity, and a shorter half-life (~20–30 min).

Q: How should it be stored? Lyophilized: -20°C to -80°C, sealed, away from light. Reconstituted: aliquoted at -80°C, used within 24–48 hours after thawing to working dilution.

---

Supporting Articles in This Cluster

This pillar page is supported by 12 in-depth articles covering each major topic in detail:

Informational and Scientific Depth

• IGF-1 LR3 Research Peptide vs Standard IGF-1: Structural Differences and Lab Research Implications
• IGF-1 LR3 Mechanism of Action in Cell Proliferation and Differentiation Research
• Structural Modifications of IGF-1 LR3 Research Peptide: Arginine Substitution and N-Terminal Extension Explained
• IGF-1 LR3 vs IGF-1 DES: Comparative Analysis for Preclinical Research Protocols

Lab How-To and Practical Guides

• How to Reconstitute IGF-1 LR3 Research Peptide: Step-by-Step Lab Protocol
• Optimal Storage and Stability Guidelines for IGF-1 LR3 Lyophilized Research Peptide
• Receptor Grade IGF-1 LR3 Research Peptide: Why Purity Standards Matter in Experiments

Commercial and Buyer Intent

• How to Choose a Trusted Supplier for IGF-1 LR3 Research Peptides in 2026
• Quality Testing and Third-Party Verification for IGF-1 LR3 Research Peptides
• IGF-1 LR3 Research Peptide Half-Life and Stability Advantages for Long-Term Lab Studies
• Buying IGF-1 LR3 Online for Research: Key Factors Researchers Should Consider
• Applications of IGF-1 LR3 Research Peptide in Preclinical Tissue Repair and Regeneration Studies

---

References

1. Adams, T. E., Epa, V. C., Garrett, T. P., & Ward, C. W. (2000). Structure and function of the type 1 insulin-like growth factor receptor. Cellular and Molecular Life Sciences, 57(7), 1050–1093.
2. Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology-Endocrinology and Metabolism, 278(6), E967–E976.
3. Cascieri, M. A., Chicchi, G. G., Applebaum, J., Hayes, N. S., Green, B. G., & Bayne, M. L. (1988). Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor. Biochemistry, 27(10), 3229–3233.
4. Clemmons, D. R. (2001). Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocrine Reviews, 22(6), 800–817.
5. Coolican, S. A., Samuel, D. S., Bhatt, D. L., McWade, F. J., & Bhatt, D. L. (1997). The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. Journal of Biological Chemistry, 272(10), 6653–6662.
6. Florini, J. R., Ewton, D. Z., & Coolican, S. A. (1996). Growth hormone and the insulin-like growth factor system in myogenesis. Endocrine Reviews, 17(5), 481–517.
7. Francis, G. L., Ross, M., Ballard, F. J., Milner, S. J., Bhala, A., Bettis, J. M., ... & Wallace, J. C. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213–223.
8. Jones, J. I., & Clemmons, D. R. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews, 16(1), 3–34.
9. LeRoith, D., Werner, H., Beitner-Johnson, D., & Roberts, C. T. (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews, 16(2), 143–163.
10. Loeser, R. F., Goldring, S. R., Scanzello, C. R., & Goldring, M. B. (2014). Osteoarthritis: a disease of the joint as an organ. Arthritis & Rheumatology, 64(6), 1697–1707.
11. Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer, 8(12), 915–928.
12. Zhao, G., Monier-Faugere, M. C., Langub, M. C., Geng, Z., Nakayama, T., Pike, J. W., ... & Malluche, H. H. (2000). Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology, 141(7), 2674–2682.

---

Disclaimer: IGF-1 LR3 is sold by Palmetto Peptides exclusively for in vitro and preclinical laboratory research by qualified researchers in authorized settings. It is not approved by the FDA for human or veterinary use and must not be used for any application outside of controlled research. Palmetto Peptides makes no claims regarding the safety, efficacy, or therapeutic value of this compound in humans or animals. All research must comply with applicable institutional, state, and federal regulations.

---

Author: Palmetto Peptides Research Team Last Updated: March 30, 2026

Research-grade IGF-1 LR3 is available from Palmetto Peptides.